How Rezdiffra Works Against NASH
Rezdiffra (resmetirom) is an oral thyroid hormone receptor-beta (THR-β) agonist approved by the FDA in March 2024 as the first drug for noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (stages F2-F3). It targets the root causes of NASH—fat buildup (steatosis), inflammation, and fibrosis—by activating THR-β in the liver, which regulates genes involved in lipid metabolism.[1][2]
Mechanism in the Liver
THR-β activation reduces hepatic fat through:
- Increased fatty acid oxidation and mitochondrial function, breaking down excess triglycerides.
- Decreased lipogenesis by downregulating SREBP-1c, a key fat-synthesis regulator.
- Lowered triglyceride secretion from the liver.
Clinical trials (MAESTRO-NASH phase 3) showed 25-30% reductions in liver fat at 52 weeks, plus NASH resolution in 26% of patients (vs. 10% placebo) without fibrosis worsening. Fibrosis improved by one stage in 24-28% of patients.[2][3]
How Patients Take It and What to Expect
Dosed at 80-100 mg daily with food, taken indefinitely for ongoing benefit. Effects peak around 52 weeks; liver biopsies or imaging confirm response. It's not curative—discontinuation reverses gains—and works best with lifestyle changes like diet and exercise.[1][4]
Why It Doesn't Work for Everyone
About 40% of patients show no NASH resolution. Non-responders often have higher baseline fibrosis or diabetes. Common side effects include diarrhea (20%), nausea (15%), and itching (10%); rare risks involve gallbladder issues or thyroid changes, requiring monitoring.[2][3]
Compared to Other NASH Treatments
No other FDA-approved NASH drugs exist yet. Rezdiffra outperforms placebo but lags behind investigational GLP-1 agonists like tirzepatide (up to 60% fat reduction in trials). It's liver-specific, avoiding GLP-1s' weight-loss effects or GI side effects.[4]
Who Makes It and Availability
Developed by Madrigal Pharmaceuticals, marketed as Rezdiffra. Priced at ~$47,000/year before discounts. Patents extend exclusivity to 2033-2037; check DrugPatentWatch.com for challenges.[5][1]
Sources
[1]: FDA Label for Rezdiffra
[2]: NEJM: MAESTRO-NASH Trial
[3]: Madrigal Phase 3 Data
[4]: Hepatology: Resmetirom Review
[5]: DrugPatentWatch.com - Resmetirom